Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Perrigo Company    PRGO

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 5 464 M
EBIT 2016 1 414 M
Net income 2016 -55,3 M
Debt 2016 5 382 M
Yield 2016 0,82%
Sales 2017 5 251 M
EBIT 2017 1 214 M
Net income 2017 466 M
Debt 2017 3 893 M
Yield 2017 0,84%
P/E ratio 2016 -
P/E ratio 2017 21,69
EV / Sales2016 2,95x
EV / Sales2017 2,78x
Capitalization 10 720 M
More Financials
Company
Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products.It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences.The CHC segment includes... 
Sector
Pharmaceuticals
Calendar
03/01Ex-dividend day
More about the company
Surperformance© ratings of Perrigo Company
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY
04:38p PERRIGO COMPANY PLC : Pawar Law Group Announces Investigation of Securities Clai..
04:21p EpiPen maker Mylan forecasts strong 2017; shares jump
01:01p PERRIGO COMPANY PLC ORDINARY SHARES : PRGO) Sells Rights To Tysabri
02/28 Target and Perrigo plunge; Nutrisystem surges
02/28 Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Perri..
02/28 PERRIGO : plunges on sale of Tysabri rights
02/28 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Perrigo Company..
02/28 Rosen Law Firm Announces Investigation of Securities Claims Against Perrigo C..
02/28 PERRIGO CO PLC : Entry into a Material Definitive Agreement, Other Events (form ..
02/28 PERRIGO : CFO resigns to take job at Amgen
More news
Sector news : Pharmaceuticals - NEC
07:15p Banks, builders boost European shares as Trump-trade back on
04:21p EpiPen maker Mylan forecasts strong 2017; shares jump
12:41p Bayer sells 11 percent of Covestro for 1.46 billion euros
11:18a Banks, basic resources lift European shares on Trump-trade
09:44aDJCovestro Shares Nosedive After Bayer Reduces Stake
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 18
Average target price 86,9 $
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John T. Hendrickson President, Chief Executive Officer & Director
Mary Lauren Brlas Chairman
Judy L. Brown Executive VP, Chief Financial & Accounting Officer
Thomas Farrington Chief Information Officer & Executive VP
Grainne Quinn Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY12 141
JOHNSON & JOHNSON6.24%332 993
ROCHE HOLDING LTD.4.73%209 283
PFIZER INC.5.48%204 030
NOVARTIS AG5.06%203 039
MERCK & CO., INC.12.38%181 558
More Results